Table 1.
In-silico screening led to 12 candidate drugs
| Drug | Indication | Publication in PubMed | Clinical Trial | |
|---|---|---|---|---|
| Brain cancer | Other Cancers | |||
| Norcyclobenzaprine | Depression | Yes | NA | NA |
| Protriptyline | Depression | NA | Prostate cancer | NA |
| Iobenguane | Neuroblastoma | Yes | NA | Pheochromocytoma and paraganglioma: FDA approved (AZEDRA) |
| Haloperidol |
Schizophrenia Tourette's disorder |
Yes | Pancreatic cancer | NA |
| Alimemazine | Sedative | NA | Colon cancer | NA |
| Nortriptyline | Depression | NA | Bladder tumor, multiple myeloma, osteosarcoma and prostate cancer | Relapsed Small Cell Carcinoma: Phase I (NCT02881125) |
| Melatonin | Sleep cycle support | Yes | Pan-cancer | 30 completed clinical trials in multiple oncological indications |
| Trifluoperazine | Schizophrenia | Yes | Breast cancer, colon cancer, lung cancer, lymphoma, multiple myeloma ovarian cancer and pancreatic cancer | Doxorubicin resistance cancer: Phase I/II |
| Perphenazine |
Schizophrenia Nausea Vomiting |
Yes | Breast cancer, colon cancer, endometrial cancer, leukemia, melanoma and pancreatic cancer | NA |
| Spiperone | Schizophrenia | Yes | Gastric cancer | NA |
| Imipramine | Depression | Yes | Colon cancer, small cell lung cancer | Breast Cancer: Early phase I (NCT03122444) |
| Levomepromazine |
Psychosis Schizophrenia Bipolar disorder Nausea Insomnia |
NA | Breast cancer and leukemia | NA |